Europe
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Recursion entered into a billion-dollar “transformational collaboration” with Roche to identify and develop up to 40 new medications for neuroscience and oncology.
LAG-3 is a priority focus in cancer immunotherapy because its inhibition has the potential to make PD-1 inhibitors work in more patients.
Life sciences investors are being anything but shy as the end of 2021 draws near. Here are a few companies that are still seeing cash come in the door as December gets underway.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
Called “blastoids,” the alternative embryo-like structures are grown for up to 13 days in the lab for use in different types of studies on the behavior of human embryos.
Novartis held an investor event to discuss their research programs, highlighting its partnership with Belgian pharma company UCB worth up to $1.5 billion.
GlaxoSmithKline said early research shows its monoclonal antibody is demonstrating efficacy against the newest strain of COVID-19.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
PRESS RELEASES